/ n :	∠' •								
_	J11								
2/10/01	31 U.S.	UTILITY PATENT APPLICATION TRANSMITTAL (Under 37 C.F.R. §1.53(b))	Docket No.: V-262.00 Page 1 of 2 Title: Enveloped Virus Vaccine and Method for Production Express Mail Label No.: (n/a)						
	TO IN	APPLICATION ELEMENTS /ENTORS: Otfried Kistner	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231						
and પેક્ષામાં માતા પાતામાં પાતામાં પાતામાં પાતામાં માતા કર્યા છે. આ પાતામાં માતા અનીક પીતામાં પાતામાં પાતામામાં પાતામાં પાતામાં પાતામાં પાતામાં પાતામાં પાતામાં પાતામા પાતામાં પાતામ	1. 2. 3. 4.	X Fee Transmittal Form (Submit an original, and a duplicate for fee processing) X Specification [Total Pages 23] X Drawing(s) (35 USC §113) [Total Pages 1] X Signed Declaration [Total Pages 1] a. Newly executed (original or copy) b. Copy from a prior application (37 CFR §1.63(d)) A A A A A A A A A A	10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations 11. Preliminary Amendment 12. Return Receipt Postcard (MPEP 503) 13. Small Entity Statement(s) 14. Certified Copy of Priority Documents (s) 15a. Cancel in the application original claims before calculating the filing fee 15b. Amend the specification by inserting before the first line the sentence:This is a Continuation, Divisional, Continuation-in-part, of application filed 15c. I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application number, filed aAnd further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any						
	a. b. c.	Computer Readable Copy Paper Copy (identical to computer copy) Statement Verifiying identify of above copies	Patent issuing thereon.						

OT	APPLICATION ELEMENTS	ADDRESS TO: Assistant Commissioner for Patents						
IN	VENTORS: Otfried Kistner Manfred Reiter Axel Bruehmann Noel Barrett Wolfgang Mundt Friedrich Dorner	Box Patent Application Washington, D.C. 20231 OLUMO 10900000000000000000000000000000000000						
1.	X Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	10. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations						
2.	X Specification [Total Pages 23]	11. Preliminary Amendment						
3.	X Drawing(s) (35 USC §113) [Total Pages (Fig. 1A & 1B)]	12. Return Receipt Postcard (MPEP 503)						
4.	Signed Declaration [Total Pages]	13. Small Entity Statement(s)						
("H ("H ("H	a. Newly executed (original or copy)	14. Certified Copy of Priority Documents (s)						
	b. Copy from a prior application (37 CFR §1.63(d))	15a. Cancel in the application original claimsbefore calculating the filing fee						
4	i. DELETION OF INVENTOR(S)	15b. Amend the specification by inserting before the first line the sentence:This is a Continuation,						
linii Di	Signed statement attached deleting invento named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)	Divisional, Continuation-in-part, of application, filed						
ալ (¹ 5.	Incorporation By Reference (useable if Box 4b is checked.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application number, filed aAnd further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are						
6.	Nucleotide and/or Amino Acid Sequence Submission	punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any						
a. b. c.	Computer Readable Copy Paper Copy (identical to computer copy) Statement Verifiying identify of above copies	Patent issuing thereon.						
7.	Assignment Papers (cover sheet & document(s))							
8.	37 CFR §3.73(b) Statement Power of Attorney	15d. Other:						
9.	English Translation Document	15e. Other						
16.	If a CONTINUING APPLICATION, check appropriate box and supp	ly the requisite information:						
	Continuation Divisional Continuation	n-in-part (CIP) of prior application No.:						

UTILITY PATENT

APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: V-262.00

Page 2 of 2

Title: Enveloped Virus Vaccine and Method for Production

Express Mail Label No.: (n/a)

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS	
	TOTAL CLAIMS (37 CFR 1.16(b))	25-20 =	5	X \$ 18 =	\$90.00	
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	7-3 =	4	X \$ 84 =	\$336.00	
	MULTIPLE DEPENDEN (37 CFR §1.16(d))	T CLAIMS (if app	licable)	+ \$ 280 =	\$ 0	
1 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1				BASIC FEE (37 CFR §1.16(a))	\$740.00	
				TOTAL =	\$1166.00	

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket V-262.00).

(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

a.	Х	Fees required under 37 CFR §1.16
----	---	----------------------------------

b. X Fees required under 37 CFR §1.17

c. X Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	C. Joseph Faraci, Reg. No. 32,350	
SIGNATURE	C Jept San	
DATE	December 6, 2001	

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation P.O. Box 15210 Irvine, California 92614

Telephone: (949) 250-6827 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby	certify_t												
Label No. 🔄	, 1	in an er	velope ac	ldressed to	o: Box F	atent Appli	cation, A	Assistant	Commissi	oner for	Patents.	Washin	eton. D.C
20231 on 🔼 🔻	٠٠,٫٫,		****,,,	** ** /	er afa	1.1	1		·	,	٠, ٢	; ; '	3.44 2

By: